

Anders Sundin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3455768/publications.pdf>

Version: 2024-02-01

85
papers

5,668
citations

196777

29
h-index

87275

74
g-index

87
all docs

87
docs citations

87
times ranked

5242
citing authors

#	ARTICLE	IF	CITATIONS
1	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13040.	1.2	12
2	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13044.	1.2	14
3	Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study). <i>Cancers</i> , 2022, 14, 1040.	1.7	2
4	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13105.	1.2	12
5	Commentary on Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant masses. <i>European Journal of Endocrinology</i> , 2022, , .	1.9	1
6	Primary hyperparathyroidism, a machine learning approach to identify multiglandular disease in patients with a single adenoma found at preoperative Sestamibi-SPECT/CT. <i>European Journal of Endocrinology</i> , 2022, 187, 257-263.	1.9	5
7	Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability. <i>Neuroendocrinology</i> , 2021, 111, 831-839.	1.2	7
8	Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 962.	1.7	25
9	Prospective data-driven respiratory gating of [⁶⁸ Ga]Ga-DOTATOC PET/CT. <i>EJNMMI Research</i> , 2021, 11, 33.	1.1	9
10	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	1.3	120
11	Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with ¹⁷⁷ Lu-DOTATATE. <i>Endocrine Connections</i> , 2021, 10, 422-431.	0.8	5
12	Interobserver agreement of transvaginal ultrasound and magnetic resonance imaging in local staging of cervical cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 773-779.	0.9	6
13	⁶⁸ Ga-DOTATOC PET/MRI and ¹¹ C-5-HTP PET/MRI are superior to ⁶⁸ Ga-DOTATOC PET/CT for neuroendocrine tumour imaging. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12981.	1.2	12
14	The preoperative localisation of small parathyroid adenomas improves when adding Tc-99m-Sestamibi SPECT to multiphase contrast-enhanced CT. <i>Insights Into Imaging</i> , 2021, 12, 72.	1.6	1
15	Knee function 30 years after ACL reconstruction: a case series of 60 patients. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021, 92, 716-721.	1.2	1
16	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. <i>Journal of Nuclear Medicine</i> , 2021, 62, 26S-33S.	2.8	8
17	Adrenal myelolipomas. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 767-775.	5.5	49
18	Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by ⁶⁸ Ga-DOTATOC PET/CT. <i>EJNMMI Research</i> , 2021, 11, 118.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus. , 2021, , .		2
20	Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology, 2020, 110, 217-224.	1.2	25
21	Higher frequency of osteoarthritis in patients with ACL graft rupture than in those with intact ACL grafts 30Ayears after reconstruction. Knee Surgery, Sports Traumatology, Arthroscopy, 2020, 28, 2139-2146.	2.3	14
22	TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma. BMC Cancer, 2020, 20, 1197.	1.1	7
23	Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients. Frontiers in Oncology, 2020, 10, 193.	1.3	7
24	Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 844-860.	0.6	571
25	Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study. Clinical Cancer Research, 2019, 25, 6692-6699.	3.2	18
26	Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their "Letter to the Editor" Neuroendocrinology, 2019, 108, 366-366.	1.2	0
27	11C-hydroxy-ephedrine-PET/CT in the Diagnosis of Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 847.	1.7	18
28	Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. Cancers, 2019, 11, 909.	1.7	56
29	Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients'™ Outcome in Neuroendocrine Tumors (NET)"The GREPONET Study. Oncologist, 2019, 24, e1082-e1090.	1.9	26
30	Multiphase Iodine Contrast-Enhanced SPECT/CT Outperforms Nonenhanced SPECT/CT for Preoperative Localization of Small Parathyroid Adenomas. Clinical Nuclear Medicine, 2019, 44, 929-935.	0.7	15
31	Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. Neuroendocrinology, 2019, 108, 45-53.	1.2	22
32	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology, 2019, 108, 26-36.	1.2	46
33	Anatomic distribution of hematoma following pelvic fracture. British Journal of Radiology, 2018, 91, 20170840.	1.0	10
34	Preoperative ⁶⁸ Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions. World Journal of Surgery, 2018, 42, 498-505.	0.8	26
35	Novel Functional Imaging of Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2018, 47, 505-523.	1.2	13
36	Additional value of tumour growth rate (TGR) in patients (pts) diagnosed with well-differentiated neuroendocrine tumours (NETs) achieving RECIST-defined stable disease (SD): Subgroup analysis of the GREPONET study.. Journal of Clinical Oncology, 2018, 36, 4094-4094.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study. <i>International Journal of Endocrine Oncology</i> , 2017, 4, 9-22.	0.4	0
38	Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸ Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸ F- ¹⁸ F-DOPA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1588-1601.	3.3	319
39	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. <i>Neuroendocrinology</i> , 2017, 105, 212-244.	1.2	325
40	¹⁸ F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas. <i>Clinical Nuclear Medicine</i> , 2017, 42, 81-82.	0.7	1
41	Predictive value of [¹⁸ F]-fluoride PET for monitoring bone remodeling in patients with orthopedic conditions treated with a Taylor spatial frame. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 441-448.	3.3	2
42	Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. <i>Oncotarget</i> , 2017, 8, 78573-78587.	0.8	5
43	Preoperative MR staging of cervical carcinoma: are oblique and contrast-enhanced sequences necessary?. <i>Acta Radiologica Open</i> , 2016, 5, 205846011667946.	0.3	6
44	Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 114, 872-880.	2.9	41
45	Assessment of Whether Patients' Knowledge, Satisfaction, and Experience Regarding Their ¹⁸ F-Fluoride PET/CT Examination Affects Image Quality. <i>Journal of Nuclear Medicine Technology</i> , 2016, 44, 21-25.	0.4	10
46	Multidetector CT of pancreatic ductal adenocarcinoma: Effect of tube voltage and iodine load on tumour conspicuity and image quality. <i>European Radiology</i> , 2016, 26, 4021-4029.	2.3	13
47	Radiological Imaging: Computed Tomography, Magnetic Resonance Imaging and Ultrasonography. <i>Frontiers of Hormone Research</i> , 2015, 44, 58-72.	1.0	8
48	Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2015, 56, 177-182.	2.8	179
49	Evaluation of a new system for chest tomosynthesis: aspects of image quality of different protocols determined using an anthropomorphic phantom. <i>British Journal of Radiology</i> , 2015, 88, 20150057.	1.0	5
50	Recent developments in imaging of pancreatic neuroendocrine tumors. <i>Annals of Gastroenterology</i> , 2015, 28, 193-202.	0.4	38
51	Can Na ¹⁸ F PET/CT Be Used to Study Bone Remodeling in the Tibia When Patients Are Being Treated with a Taylor Spatial Frame?. <i>Scientific World Journal</i> , The, 2014, 2014, 1-9.	0.8	5
52	¹¹ C-Hydroxyephedrine Positron Emission Tomography in the Postoperative Management of Pheochromocytoma and Paraganglioma. <i>Neuroendocrinology</i> , 2014, 100, 60-70.	1.2	2
53	Positron Emission Tomography Ligand [¹¹ C]5-Hydroxy-Tryptophan Can Be Used as a Surrogate Marker for the Human Endocrine Pancreas. <i>Diabetes</i> , 2014, 63, 3428-3437.	0.3	59
54	Neuroendocrine tumours: the role of imaging for diagnosis and therapy. <i>Nature Reviews Endocrinology</i> , 2014, 10, 102-114.	4.3	120

#	ARTICLE	IF	CITATIONS
55	Quantitative and Qualitative Inpatient Comparison of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE: Net Uptake Rate for Accurate Quantification. <i>Journal of Nuclear Medicine</i> , 2014, 55, 204-210.	2.8	135
56	Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. <i>Journal of Hepatology</i> , 2014, 61, 1352-1357.	1.8	25
57	Comparative Biodistribution and Radiation Dosimetry of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1755-1759.	2.8	123
58	PET-Guided Surgery – High Correlation between Positron Emission Tomography with ¹¹ C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours. <i>Cancers</i> , 2012, 4, 100-112.	1.7	13
59	¹¹ C-Hydroxyephedrine Positron Emission Tomography Imaging of Pheochromocytoma: A Single Center Experience over 11 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2423-2432.	1.8	25
60	Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead. <i>Neuroendocrinology</i> , 2012, 96, 261-271.	1.2	51
61	Imaging of neuroendocrine tumors. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 473-483.	1.6	5
62	¹¹ C-5-hydroxytryptophan positron emission tomography after radiofrequency ablation of neuroendocrine tumor liver metastases. <i>Nuclear Medicine and Biology</i> , 2012, 39, 883-890.	0.3	3
63	Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 803-818.	1.0	97
64	ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2010, 91, 341-350.	1.2	65
65	The value of ¹¹ C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 794-799.	1.8	22
66	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations. <i>Neuroendocrinology</i> , 2009, 90, 167-183.	1.2	246
67	Gastroenteropancreatic neuroendocrine tumours. <i>Lancet Oncology</i> , 2008, 9, 61-72.	5.1	1,474
68	Nuclear imaging of neuroendocrine tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 69-85.	2.2	141
69	Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with ¹¹ C-5-hydroxytryptophan positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 60-65.	3.3	78
70	Whole-Body ¹¹ C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3392-3400.	1.8	296
71	PET in the Diagnosis of Neuroendocrine Tumors. <i>Annals of the New York Academy of Sciences</i> , 2004, 1014, 246-257.	1.8	98
72	Octreoscan in patients with bronchial carcinoid tumours. <i>Clinical Endocrinology</i> , 2003, 59, 793-799.	1.2	107

#	ARTICLE	IF	CITATIONS
73	Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivoâ€”tumor visualization using positron emission tomography with ¹¹ C-harmine. <i>Nuclear Medicine and Biology</i> , 2003, 30, 669-679.	0.3	30
74	Cellular uptake and processing of directly and indirectly ¹²⁵ I-iodinated and ⁷⁶ Br-brominated monoclonal antibody A33. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S712-S714.	0.5	3
75	Demonstration of [¹¹ C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. <i>Nuclear Medicine and Biology</i> , 2000, 27, 33-41.	0.3	42
76	Kinetics of ⁷⁶ Br-labeled anti-CEA antibodies in pigs; Aspects of dosimetry and PET imaging properties. <i>Medical Physics</i> , 1999, 26, 249-258.	1.6	15
77	Whole-Body PET with [¹¹ C]-5-Hydroxytryptophan for Localization of Neuroendocrine Tumors. <i>Molecular Imaging and Biology</i> , 1999, 2, 338.	0.3	2
78	Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2534-2541.	0.8	144
79	[¹⁸ F] FDG PET in Gastric Non-Hodgkin's Lymphoma. <i>Acta OncolÃ³gica</i> , 1997, 36, 577-584.	0.8	38
80	PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. <i>Journal of Nuclear Medicine</i> , 1996, 37, 1766-70.	2.8	62
81	Radioimmunolocalization of Hepatic Metastases and Subcutaneous Xenografts from a Human Colonic Cancer: In the Nude Rat: Aspects of Tumour Implantation Site and Mode of Antibody Administration. <i>Acta OncolÃ³gica</i> , 1993, 32, 877-885.	0.8	4
82	Radioimmunolocalization and quantification of liver metastases and subcutaneous tumours from a human colonic cancer xenografted in the nude rat. <i>Acta Radiologica Supplementum</i> , 1993, 382, 1-29.	0.5	0
83	Contrast-enhanced CT scanning in vivo for the quantification of hepatic metastases from a human colonic cancer in the nude rat. <i>European Journal of Surgical Oncology</i> , 1992, 18, 615-23.	0.5	5
84	Radioimmunolocalization of human colonic cancer xenografts; aspects of extensive purification of monoclonal anti-CEA-antibodies. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1991, 18, 891-899.	0.3	1
85	Neuroendocrine Tumors. , 0, , 564-668.		0